Frankfurt - Delayed Quote EUR

Danaher Corporation (DAP.F)

Compare
229.40
-1.15
(-0.50%)
As of 8:01:04 AM GMT+1. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
23,742,000.00
23,890,000.00
26,643,000.00
24,802,000.00
22,284,000.00
Cost of Revenue
9,647,000.00
9,856,000.00
10,455,000.00
9,563,000.00
9,809,000.00
Gross Profit
14,095,000.00
14,034,000.00
16,188,000.00
15,239,000.00
12,475,000.00
Operating Expense
9,243,000.00
8,755,000.00
8,652,000.00
8,852,000.00
8,244,000.00
Operating Income
4,852,000.00
5,279,000.00
7,536,000.00
6,387,000.00
4,231,000.00
Net Non Operating Interest Income Expense
-82,000.00
17,000.00
-163,000.00
-220,000.00
-204,000.00
Other Income Expense
-207,000.00
-252,000.00
-227,000.00
344,000.00
468,000.00
Pretax Income
4,563,000.00
5,044,000.00
7,146,000.00
6,511,000.00
4,495,000.00
Tax Provision
629,000.00
823,000.00
818,000.00
1,064,000.00
849,000.00
Net Income Common Stockholders
3,892,000.00
4,743,000.00
7,103,000.00
6,269,000.00
3,510,000.00
Average Dilution Earnings
--
--
--
--
1,000.00
Diluted NI Available to Com Stockholders
3,892,000.00
4,743,000.00
7,103,000.00
6,269,000.00
3,510,000.00
Basic EPS
5.29
6.44
9.80
8.77
4.97
Diluted EPS
5.24
6.38
9.66
8.61
4.89
Basic Average Shares
735,300.00
736,500.00
725,100.00
714,600.00
706,200.00
Diluted Average Shares
741,600.00
743,100.00
737,100.00
736,800.00
718,700.00
Total Operating Income as Reported
4,775,000.00
5,202,000.00
7,536,000.00
6,377,000.00
4,231,000.00
Total Expenses
18,890,000.00
18,611,000.00
19,107,000.00
18,415,000.00
18,053,000.00
Net Income from Continuing & Discontinued Operation
3,892,000.00
4,764,000.00
7,209,000.00
6,433,000.00
3,646,000.00
Normalized Income
4,114,189.79
4,437,783.00
6,568,106.00
5,195,900.00
3,283,483.00
Interest Income
220,000.00
303,000.00
41,000.00
11,000.00
71,000.00
Interest Expense
302,000.00
286,000.00
204,000.00
231,000.00
275,000.00
Net Interest Income
-82,000.00
17,000.00
-163,000.00
-220,000.00
-204,000.00
EBIT
4,865,000.00
5,330,000.00
7,350,000.00
6,742,000.00
4,770,000.00
EBITDA
7,180,000.00
7,496,000.00
9,482,000.00
8,804,000.00
6,545,000.00
Reconciled Cost of Revenue
9,647,000.00
9,856,000.00
10,455,000.00
9,563,000.00
9,809,000.00
Reconciled Depreciation
2,315,000.00
2,166,000.00
2,132,000.00
2,062,000.00
1,775,000.00
Net Income from Continuing Operation Net Minority Interest
3,934,000.00
4,221,000.00
6,328,000.00
5,447,000.00
3,646,000.00
Total Unusual Items Excluding Goodwill
-209,000.00
-259,000.00
-271,000.00
300,000.00
447,000.00
Total Unusual Items
-209,000.00
-259,000.00
-271,000.00
300,000.00
447,000.00
Normalized EBITDA
7,389,000.00
7,755,000.00
9,753,000.00
8,504,000.00
6,098,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-28,810.21
-42,217.00
-30,894.00
48,900.00
84,483.00
12/31/2020 - 3/5/2001

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NN6.F NanoRepro AG
1.4800
+5.34%
 
ESF0.MU Eurofins Scientific SE
50.22
+2.03%
 
IDHCl.XC
 
TN8.F Thermo Fisher Scientific Inc.
527.70
-1.27%
 
MVF.AX Monash IVF Group Limited
1.2050
-2.82%
 
VIMIAN.ST Vimian Group AB (publ)
36.90
-0.40%
 
PRM.L Proteome Sciences plc
4.8000
+40.35%
 
GDR.L genedrive plc
2.1940
+2.05%
 
SZLS.TO StageZero Life Sciences Ltd.
0.0400
0.00%
 
LZAGY Lonza Group AG
60.46
-0.05%